Fousseni Soulama, Ngangue Patrice, Barro Abibata, Ramde Sophie Wendkoaghenda, Bihina Luc Thierry, Ngoufack Marie Nicole, Bayoulou Souleymane, Kiki Gbetogo Maxime, Salfo Ouedraogo
School of Public Health, Texila American University of Zambia, Lilayi 10101, Zambia.
Faculty of Nursing, Laval University, Quebec, QC G1V 0A6, Canada.
Vaccines (Basel). 2025 Mar 4;13(3):269. doi: 10.3390/vaccines13030269.
Over the past 50 years, developing new vaccines has been pivotal in responding to emerging and re-emerging diseases globally. However, despite substantial partner support, introducing new vaccines in sub-Saharan Africa remains challenging. This systematic review documents the barriers to new vaccine introduction in sub-Saharan Africa by distinguishing between vaccines integrated into routine immunization programs and those introduced primarily for outbreak response. A comprehensive electronic search was conducted across five databases for articles published in English or French on the challenges of new vaccine introduction in sub-Saharan Africa. Three reviewers screened articles independently based on the titles and abstracts, with full-text assessments conducted for inclusion. Data were analyzed thematically and synthesized narratively. A total of 796 articles were retrieved from the five databases. Following the screening, 33 articles were finally retained and included in the review. These articles concerned the introduction of eight new vaccines (malaria vaccine, COVID-19 vaccine, HPV vaccine, Ebola vaccine, cholera vaccine, hepatitis B vaccine, rotavirus vaccine, and typhoid vaccine). The analyses revealed coordination and financing challenges for six vaccines in seventeen countries, acceptability challenges for five vaccines in ten countries, logistical challenges for two vaccines in six countries, and quality service delivery challenges for three vaccines in thirteen countries. Addressing the challenges of introducing new vaccines in sub-Saharan Africa requires targeted, evidence-based strategies. Prioritizing political commitment, innovative funding, public education, workforce development, and infrastructure improvements will strengthen immunization systems and enable timely vaccine delivery. Collaborative efforts and a focus on local context can advance equitable health outcomes, safeguard public health, and support global immunization goals.
在过去50年里,研发新疫苗对于全球应对新出现和再度出现的疾病至关重要。然而,尽管有大量伙伴的支持,但在撒哈拉以南非洲地区引入新疫苗仍然具有挑战性。本系统综述通过区分纳入常规免疫规划的疫苗和主要为应对疫情而引入的疫苗,记录了撒哈拉以南非洲地区新疫苗引入的障碍。我们在五个数据库中进行了全面的电子搜索,以查找用英文或法文发表的关于撒哈拉以南非洲地区新疫苗引入挑战的文章。三位评审员根据标题和摘要独立筛选文章,并进行全文评估以确定是否纳入。对数据进行了主题分析并进行了叙述性综合。从这五个数据库中总共检索到796篇文章。经过筛选,最终保留了33篇文章并纳入综述。这些文章涉及八种新疫苗(疟疾疫苗、新冠疫苗、人乳头瘤病毒疫苗、埃博拉疫苗、霍乱疫苗、乙肝疫苗、轮状病毒疫苗和伤寒疫苗)的引入。分析揭示了17个国家中六种疫苗面临的协调和资金挑战、10个国家中五种疫苗面临的可接受性挑战、6个国家中两种疫苗面临的后勤挑战以及13个国家中三种疫苗面临的优质服务提供挑战。应对撒哈拉以南非洲地区新疫苗引入的挑战需要有针对性的、基于证据的策略。优先考虑政治承诺、创新资金、公众教育、劳动力发展和基础设施改善将加强免疫接种系统,并确保疫苗及时交付。合作努力并关注当地情况可以促进公平的健康成果、保障公众健康并支持全球免疫目标。